These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15846083)

  • 1. p53 gain-of-function: tumor biology and bioinformatics come together.
    Koonin EV; Rogozin IB; Glazko GV
    Cell Cycle; 2005 May; 4(5):686-8. PubMed ID: 15846083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection.
    Glazko GV; Koonin EV; Rogozin IB
    Biochim Biophys Acta; 2004 Aug; 1679(2):95-106. PubMed ID: 15297143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
    Stein T; Crighton D; Boyle JM; Varley JM; White RJ
    Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
    Gonzalez K; Fong C; Buzin C; Sommer SS; Saldivar JS
    Curr Protoc Hum Genet; 2008 Apr; Chapter 10():Unit 10.10. PubMed ID: 18428420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
    Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
    Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Germline mutations of the p53 gene].
    Frebourg T
    Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 gain-of-function in cancer.
    Oren M; Rotter V
    Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of p53 tumor suppressor gene in families with multiple glioma patients.
    Paunu N; Syrjäkoski K; Sankila R; Simola KO; Helén P; Niemelä M; Matikainen M; Isola J; Haapasalo H
    J Neurooncol; 2001 Dec; 55(3):159-65. PubMed ID: 11859970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional functionality of germ line p53 mutants influences cancer phenotype.
    Monti P; Ciribilli Y; Jordan J; Menichini P; Umbach DM; Resnick MA; Luzzatto L; Inga A; Fronza G
    Clin Cancer Res; 2007 Jul; 13(13):3789-95. PubMed ID: 17606709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
    Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.
    Zerdoumi Y; Aury-Landas J; Bonaïti-Pellié C; Derambure C; Sesboüé R; Renaux-Petel M; Frebourg T; Bougeard G; Flaman JM
    Hum Mutat; 2013 Mar; 34(3):453-61. PubMed ID: 23172776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.
    Jordan JJ; Inga A; Conway K; Edmiston S; Carey LA; Wu L; Resnick MA
    Mol Cancer Res; 2010 May; 8(5):701-16. PubMed ID: 20407015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.